Formulation Development
Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase 1 Clinical Trial
Recce Pharmaceuticals Ltd recently reported the final three subjects of cohort three at 500mg have been intravenously dosed in the Phase 1 intravenous (IV) clinical…
Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to….
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus Vaccine Candidate
Moderna, Inc. recently announced the Data and Safety Monitoring Board (DSMB) for the RSV program has endorsed the start of the Phase 3 portion of…
Poseida Therapeutics Appoints New President, Gene Therapy
Poseida Therapeutics, Inc. recently announced Brent Warner has joined the company as President, Gene Therapy, effective February 21, 2022. “Brent brings deep pharmaceutical expertise and…
Hovione & Zerion Pharma Announce Strategic Partnership
Hovione recently announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome, Zerion´s proprietary solubility enhancement….
Medigene & BioNTech Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
Medigene AG and BioNTech SE recently announced they have entered a multi-target research collaboration to develop T cell receptor (TCR) based….
Enteris BioPharma Highlights Progress in Oral Feasibility Program
Enteris BioPharma, Inc. recently provided an update on its oral feasibility programs involving the company’s Peptelligence and ProPerma oral peptide and small….
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ Technology Can Identify T-Cell Receptors Associated With Crohn’s Disease
Adaptive Biotechnologies Corporation recently presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress…
Recipharm Announces Acquisition of Vibalogics & Arranta Bio
Recipharm is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics and Arranta Bio….
Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform
Quotient Sciences recently announced it has integrated drug substance into its flagship Translational Pharmaceutics® platform. The newly integrated service unites drug substance, drug product, and…
Gracell Doses First Patients in First-in-Human Clinical Trial of Dual-Targeting CAR-T Therapy
Gracell Biotechnologies Inc. recently announced it has dosed multiple patients in a clinical trial evaluating GC012F, the company's autologous CAR-T therapeutic candidate dual-targeting B cell…
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial
Evelo Biosciences, Inc. recently announced the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of…
Zai Lab Announces Breakthrough Therapy Designation
Zai Lab Limited recently announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational….
Pharmazz Inc. Announces Completion of Enrollment of Phase 3 Clinical Trial
Pharmazz, Inc. recently announced its Phase 3 clinical trial evaluating sovateltide as a treatment for acute ischemic stroke is now fully enrolled. Sovateltide is a…
Veru Announces the Presentation of Updated Data From Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration Resistant Prostate Cancer
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin in 80 men with metastatic castration resistant prostate cancer…
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase 2 Portion of the OVATION 2 Study With GEN-1 in Advanced Ovarian Cancer
Celsion Corporation recently announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase 1/2 OVATION 2 Study with….
Spero Therapeutics Announces Positive Topline Results From Phase 1 Bronchoalveolar Lavage Clinical Trial
Spero Therapeutics, Inc. recently announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate.…
Hillstream BioPharma Receives Orphan Drug Designation for Uveal Melanoma Treatment
Hillstream BioPharma Inc. recently announced the FDA granted Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM). Hillstream continues to….
Adial Pharmaceuticals Announces Closing of $10 Million Financing
Adial Pharmaceuticals, Inc. recently announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately….
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Skye Bioscience, Inc. recently announced it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company’s….
